Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013–14 - Volume 21, Number 1—January 2015 - Emerging Infectious Disease journal - CDC
Volume 21, Number 1—January 2015
Oseltamivir-Resistant Influenza A(H1N1)pdm09 Viruses, United States, 2013–14
During the 2013–14 influenza season, influenza A(H1N1)pdm09 virus was the predominant circulating virus (≈80%) in the United States for the first time since the 2009 pandemic (1). We report and describe characteristics of oseltamivir-resistant influenza A(H1N1)pdm09 viruses and patients infected with these viruses in the United States.
We requested that all US state public health laboratories submit influenza-positive specimens for virologic surveillance, including antiviral susceptibility testing, as described (2). In brief, every 2 weeks each laboratory was asked to send ≤5 specimens for all virus types for virus isolation and neuraminidase (NA) inhibition assay for oseltamivir, zanamivir, and, in a subset, laninamivir and peramivir (3). All oseltamivir-resistant viruses were tested for the H275Y substitution in NA by pyrosequencing (4). Unpropagated influenza A(H1N1)pdm09 virus–positive clinical specimens were screened for the H275Y substitution by pyrosequencing (Technical Appendix[PDF - 326 KB - 4 pages]). If a cluster (>2 viruses) of oseltamivir-resistant A(H1N1)pdm09 viruses was detected, the state was asked to submit additional influenza A(H1N1)pdm09 virus specimens for testing.
Dr. Okomo-Adhiambo is a microbiologist in the Virology Surveillance and Diagnosis Branch of the Influenza Division at the Centers for Disease Control and Prevention, Atlanta, Georgia. Her primary research interest is the molecular epidemiology of influenza antiviral drug resistance.
We thank our collaborators in US public health laboratories for submitting specimens; colleagues from the Virus Reference Team, Influenza Sequence Activity Team and Molecular Epidemiology Team (Centers for Disease Control and Prevention, Atlanta, GA, USA) for providing valuable assistance; and the 2013–14 US Influenza Antiviral Working Group for providing valuable contributions to US national influenza virologic surveillance.
- Centers for Disease Control and Prevention. Seasonal influenza activity and surveillance [cited 2014 May 21]. http://www.cdc.gov/flu/weekly/
- Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010–11. Emerg Infect Dis. 2012;18:308–11 . DOIPubMed
- Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen HT, Xu X, Li Y, Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses. 2013;7:645–58. PubMed
- Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AT, Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother. 2010;54:1102–10 . DOIPubMed
- Graitcer SB, Gubareva L, Kamimoto L, Doshi S, Vandermeer M, Louie J, Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011;17:255–7 . DOIPubMed
- Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284–92 . DOIPubMed
- Centers for Disease Control and Prevention. Update: influenza activity—United States, September 28, 2008–April 4, 2009, and composition of the 2009–10 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:369–74 .PubMed
- Dharan NJ, Gubareva LV, Klimov AI, Fiore AE, Bresee JS, Fry AM. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal influenza A (H1N1) infection during the 2007–2008 influenza season in the United States. Clin Infect Dis. 2010;50:621–2 .DOIPubMed
- Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science.2010;328:1272–5 . DOI
- Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis. 2012;206:148–57 . DOI
- Meijer A, Jonges M, van Beek BP, Swaan CM, Osterhaus AD, Daniels RS, Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill. 2012;17:20266 .PubMed
- Souza TM, Resende PC, Fintelman-Rodrigues N, Gregianini TS, Ikuta N, Fernandes SB, Detection of oseltamivir-resistant pandemic influenza A(H1N1)pdm2009 in Brazil: can community transmission be ruled out? PLoS ONE. 2013;8:e80081 . DOIPubMed
- Global Initiative on Sharing All Influenza Data [cited 2014 May 21]. www.gisaid.org
- Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog. 2014;10:e1004065 . DOI
- Sun S, Wang Q, Zhao F, Chen W, Li Z. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. PLoS ONE. 2011;6:e22844 . DOI
Suggested citation for this article: Okomo-Adhiambo M, Fry AM, Su S, Nguyen HT, Elal AA, Negron E, et al. Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013–14. Emerg Infect Dis [Internet]. 2015 Jan [date cited]. http://dx.doi.org/10.3201/eid2101.141006
1Members of the 2013–14 US Antiviral Working Group are listed at the end of this article.
No hay comentarios:
Publicar un comentario